학술논문
의약품 품목갱신제도 개선에 대한 제약업계의 인식 조사
이용수 111
- 영문명
- Pharmaceutical Industry’s Perception on the Improvement of Drug Renewal System Focused on Benefit-risk Assessment
- 발행기관
- 대한약학회
- 저자명
- 박양수(Yangsu Park) 오하나(Ha-Na Oh) 여현석(Hyun Seok Yeo) 홍진태(Jin Tae Hong) 한상배(Sang-Bae Han)
- 간행물 정보
- 『약학회지』제64권 제2호(2020년), 124~135쪽, 전체 12쪽
- 주제분류
- 의약학 > 기타의약학
- 파일형태
- 발행일자
- 2020.04.30
4,240원
구매일시로부터 72시간 이내에 다운로드 가능합니다.
이 학술논문 정보는 (주)교보문고와 각 발행기관 사이에 저작물 이용 계약이 체결된 것으로, 교보문고를 통해 제공되고 있습니다.
국문 초록
영문 초록
Drug renewal system is one of the effective tools for the re-evaluation of benefit-risk for the approved drug periodically. This study was purposed to investigate pharmaceutical industry’s perception on the improvement of drug renewal system and benefit-risk assessment. Comparative analysis was conducted on domestic and foreign pharmaceutical companies, as it is expected that the survey results would be affected by differences in product types, retention level of data and infrastructure. We conducted both on-line and off-line survey, which results in a total of 77 out of 255 staffs responded from December 2019 to January 2020; most of them were working at the department of regulatory affair or pharmacovigilance. The questionnaire consisted of 3 major parts; appropriateness of the current document requirements, introduction of the benefit-risk assessment, and pharmaceutical company’s status. Sixty-five percent of the respondents said that the current document requirements for drug renewal were appropriate, though 77% responded that the current system cannot assess the benefit-risk. For the introduction of benefit-risk assessment, 57% responded that it was unnecessary. The main reason was that it was inappropriate for the domestic situation. Only 22% responded that they had a workforce for benefits-risk assessment in the company. The overall response tendency was similar between domestic and foreign companies. However, for the benefit-risk assessment method, foreign companies had a higher recognition than domestic companies (61% vs 35%). In conclusion, it was thought that the pharmaceutical industry still had a great reluctance to introduce benefit-risk assessment due to the lack of expertise and the burden of preparing documents. Therefore, it is needed that infrastructure construction and sufficient training should precede for the improvement of the drug renewal system and the introduction of a benefit-risk assessment.
목차
서 론(Introduction)
연구방법(Research Methods)
결 과(Results)
고 찰(Discussion)
결 론(Conclusion)
Conflict of Interest
References
해당간행물 수록 논문
- 장기요양시설에서의 약물 관리와 약사의 역할
- 자외선 흡광도를 이용한 유전자재조합의약품 함량 결정과정 분석
- 의약품 품목갱신제도 개선에 대한 제약업계의 인식 조사
- 실사용데이터/실사용근거를 활용한 FDA와 EMA의 규제적 의사결정 사례 분석
- 프로톤펌프저해제 사용과 폐렴 발생의 연관성
- Comparative Study of Carboplatin Dosing in Lung Cancer Patients Using the Calvert Formula and Four Equations for Estimating Glomerular Filtration Rate
- 4년근 미성숙 인삼열매 분획물의 약리학적 특성 및 치매 마우스 모델에서 인지능 개선효과
- 약물-건강기능식품 상호작용과 약물 장기 복용에 따른 영양소 결핍현상에 대한 고찰
참고문헌
교보eBook 첫 방문을 환영 합니다!
신규가입 혜택 지급이 완료 되었습니다.
바로 사용 가능한 교보e캐시 1,000원 (유효기간 7일)
지금 바로 교보eBook의 다양한 콘텐츠를 이용해 보세요!